In this issue of Cancer Cell, Nickeleit et al. (2008) identify a new proteasome inhibitor, argyrin A, and show that it induces apoptosis and inhibits angiogenesis via p27-dependent mechanisms. Their observations challenge current thinking about how this class of promising cancer therapies works and why they selectively kill cancer cells
Proteins are the basic building blocks of the human body. Most proteins, after fulfilling their func...
Protein homeostasis (in short, ‘proteostasis’) requires the timely degradation of proteins to retain...
The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apopto...
In this issue of Cancer Cell, Nickeleit et al. (2008) identify a new proteasome inhibitor, argyrin A...
AbstractThe ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellula...
Abstract: The Ubiquitin-Proteasomes System (UPS) and autophagy, two main intracellular protein degra...
The proteasome degrades approximately 80% of intracellular proteins to maintain homeostasis. Proteas...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
Prostatic carcinoma is the most prevalent cancer detected in men. Bortezomib is the first proteasome...
Tumorigenesis is often associated with an unbalanced protein homeostasis (proteostasis) network, whi...
WOS: 000347582200022PubMed ID: 25305590The 26S proteasome is a proteolytic enzyme found in both cyto...
An elegant paper by Anchoori and colleagues in this issue of Cancer Cell describes an irreversible i...
The proteasome is emerging as a target for cancer therapy because small molecule inhibitors of its c...
The 26S proteasome is a ubiquitous enzyme complex which is responsible for degrading proteins that r...
Targeted degradation of key regulatory proteins is an essential element of cell-cycle control. The p...
Proteins are the basic building blocks of the human body. Most proteins, after fulfilling their func...
Protein homeostasis (in short, ‘proteostasis’) requires the timely degradation of proteins to retain...
The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apopto...
In this issue of Cancer Cell, Nickeleit et al. (2008) identify a new proteasome inhibitor, argyrin A...
AbstractThe ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellula...
Abstract: The Ubiquitin-Proteasomes System (UPS) and autophagy, two main intracellular protein degra...
The proteasome degrades approximately 80% of intracellular proteins to maintain homeostasis. Proteas...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
Prostatic carcinoma is the most prevalent cancer detected in men. Bortezomib is the first proteasome...
Tumorigenesis is often associated with an unbalanced protein homeostasis (proteostasis) network, whi...
WOS: 000347582200022PubMed ID: 25305590The 26S proteasome is a proteolytic enzyme found in both cyto...
An elegant paper by Anchoori and colleagues in this issue of Cancer Cell describes an irreversible i...
The proteasome is emerging as a target for cancer therapy because small molecule inhibitors of its c...
The 26S proteasome is a ubiquitous enzyme complex which is responsible for degrading proteins that r...
Targeted degradation of key regulatory proteins is an essential element of cell-cycle control. The p...
Proteins are the basic building blocks of the human body. Most proteins, after fulfilling their func...
Protein homeostasis (in short, ‘proteostasis’) requires the timely degradation of proteins to retain...
The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apopto...